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Abstract
Cognitive impairment, a common finding with the brain tumors, may result from the
tumor itself or the treatment used: surgery, chemotherapy, or radiotherapy. Surgery for
brain tumors improves the cognitive function due to reduction of compression as in case
of removal of noninvasive tumors. Stability of cognitive function also was observed after
tumor resection, such as tumors of third ventricle. Postoperative cognitive worsening was
observed. Postoperative worsening of executive functions may correlate to volume of the
operated area. Cognitive deficits may follow radiotherapy by several months to many
years. These deficits may be due to vascular injury, local radionecrosis, and cerebral
atrophy. This usually involves multiple domains, including memory, attention, executive
function, and intelligence. The irradiated volume of brain tissue has great impact on
cognition. Intensity-modulated radiotherapy (IMRT) and proton beam therapy result in
greater sparing of healthy brain tissue and allow for a more-targeted delivery of radiation
and smaller penetration of tissue beyond the tumor consequently reduce the risk of
cognitive deficit after radiotherapy. Chemotherapy treatment in brain tumor seems to
have a role in cognitive dysfunction deficits. The toxicity of chemotherapy increased when
was given during or after radiotherapy. Chemotherapeutic agents, such as BCNU, CDDP,
cytosine arabinoside, and intrathecal or intravenous methotrexate, have toxic effect to the
CNS. Glioblastoma patients undergoing radiotherapy with concomitant and adjuvant
temozolomide treatment do not develop cognitive deterioration. Patients with brain
tumors face the challenge of cognitive impairment due to the tumor itself or treatments.
Cognitive deficits in processing speed, memory, attention, and executive functions
interfere with patients’ daily life activities. Cognitive rehabilitation program has proven
to be effective in patients with primary brain tumors. Cognitive impairments have a large
impact on self-care, social and professional functioning, and consequently on quality of
life. Preventing these late effects is a challenge for the medical team, psychologists, and
rehabilitation specialists. Prevention depends in part on being able to predict those at
greatest risk. Advances in neurosurgery, chemotherapy, and radiotherapy techniques
are helping to a great extent, but may not be totally successful at preventing these late effects.
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1. Introduction
1.1. Background
The term intellect designates the totality of the mental or cognitive operations that comprise
human thought, and the higher cortical functions that make up the human mind. Memory is a
specific cognitive function: the storage and retrieval of information. Other “higher” functions,
such as language, calculations, spatial topography and reasoning, music, and creativity, all
represent the functions of specific brain systems [1].
Cognitive functioning of brain tumor patients is an increasingly important outcome measure,
because cognitive impairments can have a large impact on self-care, social and professional
functioning, and consequently on quality of life (QOL) [2]. Patients with brain tumors often
experience cognitive dysfunction associated with the disease itself and its treatment, as well,
including surgery, radiotherapy (RT), and chemotherapy. Cognitive dysfunction has been
recognized as the most frequent complication among long-term survivors. Despite the many
advances made in the treatment modalities and surgical techniques, primary malignant brain
cancer is a devastating illness, characterized by poor survival rates and significant morbidity
as the disease progresses [3]. For many patients, cognitive changes are part of the disease
process, but the pattern of impairment can vary markedly in different patients.
Resection of brain tumors may result in improvement of cognitive functions. Teixidor et al. [4]
reported long-term improvement of verbal memory, after a transient immediate postopera‐
tive worsening, following frontal premotor and anterior temporal area resection, usually after
a transient immediate postoperative worsening. Cognitive improvement has also been
observed after surgical resection of high-grade gliomas [5], and in some studies stable,
cognitive performance was observed after brain tumor resection, for instance, patients with
tumors of the third ventricle [6].
Specific cognitive domain deficits after brain tumor removal were observed in some studies.
A study conducted by Goldstein et al. [7] reported minimal deterioration in attention after
right parenchymal frontal or precentral tumors resection. Another study [8] concluded that
right rather than left prefrontal cortex resection was associated with, stroop performance test,
selective attentional decline.
Radiation-induced cognitive impairment in some series is reported to occur in up to 50–90%
of adult patients with brain tumor who survive >6 months after fractionated partial or whole-
brain irradiation [9]. Moreover, because patients with brain tumor are surviving longer
because of improved radiation therapy techniques and systemic therapies [10], the patient
population experiencing these significant late effects is growing rapidly. Radiation-induced
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cognitive impairment is marked by decreased verbal memory, spatial memory, attention, and
novel problem-solving ability [11]. Modern radiation therapy techniques have resulted in
decreased acute and early delayed brain injury as well as late demyelination and white matter
necrosis with less cognitive functional deficits, including progressive memory impairments,
attention, and executive function that finally led to less impact on QOL of most survivors
[12].
Neurocognitive sequelae of chemotherapy are less well documented than radiation effects [13].
Chemotherapy-related neurotoxicity to the central nervous system may be increased by intra-
arterial administration, especially in combination with osmotic blood–brain barrier disrup‐
tion, meant to increase the local concentration of chemotherapy in the brain [14]. Neurotoxicity
may also be increased by chemotherapy given after, or even during, RT [15]. Primary central
nervous system lymphoma is chemoresponsive, such as anaplastic oligodendroglioma (AO)
and oligoastrocytoma (OA) tumors, chemotherapeutic agents are often ineffective due to
limited ability to cross the BBB. Use of radiation therapy is often associated with significant
neurotoxicity [16].
Advances in neurosurgery, chemotherapy, and RT are helping to a great extent in prevent‐
ing cognitive deficit. Prevention depends in part on being able to predict the risky factors [17].
1.2. Objectives
The chapter examines:
– Cognition and its evaluation
– Brain tumors and cognition
– Brain tumor surgery and cognition
– Effect of adjuvant therapies (radio/chemotherapy) on cognition
– Prevention or reduction of cognitive deficits during the treatment of brain tumors
– Follow-up care and cognitive rehabilitation
2. Cognition and its evaluation
2.1. Cognition
Higher brain function may be subclassified into: (a) distributed functions, which do not localize
to a particular brain region but instead require the concerted action of multiple parts on both
sides of the brain, for example, attention and concentration, memory, higher-order executive
function, social conduct, and personality; (b) localized functions, which are dependent on the
normal structure and function of a particular part of one cerebral hemisphere, for example,
language and praxis in dominant hemisphere the nondominant hemisphere hemisphere is
largely, though not exclusively, responsible for visuospatial skills [18]. Cognitive impair‐
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ment without crossing the threshold for dementia has been termed “mild cognitive impair‐
ment” (MCI) [19]. The MCI syndrome, as an expression of an incipient neurodegenerative
disorder that may lead to dementia, is extremely heterogeneous and may coexist with systemic,
neurologic, or psychiatric disorders that can cause cognitive deficits [20]. The criteria for MCI
encompassed all possible cognitive manifestations of the syndrome and four subgroups have
been proposed: deficits only in memory functions; memory deficits plus deficits in another
cognitive domain; deficits in a single nonmemory domain; and deficits in more than one
nonmemory domain [21].
2.2. Evaluation of cognitive functions
2.2.1. The Montreal cognitive assessment (MoCA)
MOCA was used as test of cognition, measure cognitive function, its cognitive domains:
visuospatial/ executive function; naming; memory; language; abstraction; and attention.
MoCA is scored out of 30 points. A normal score is 26 or above [22].
2.2.2. Mini Mental State Examination (MMSE)
MMSE is used for global cognitive functioning measurement [23].
2.2.3. Other cognitive domain-specific areas neuropsychological tests: focus on domain-specific areas of
cognition:
(1) Hayling Sentence Completion Test, Word Span and Corsi’s Test to test working memory
[24], verbal and visual memory—Recognition Memory Tests, Words, and Topography [25].
(2) Rey Auditory Verbal Learning Test—RAVLT and logical memory to assess episodic
memory, immediate and delayed recall [26], abstract reasoning: nonverbal—Raven’s ad‐
vanced progressive matrices [27, 28], verbal—Proverb Interpretation Test [29]. (3) Attention—
Digit Span sub-test from the Wechsler Adult Intelligence Scale-III [30], Elevator Counting with
Distraction from the Test of Everyday Attention [31], Trail Making test, part A and part B to
test simple speed processing and complex attention, respectively, [32]. (4) Visual perception
—Incomplete Letters Test from the Visual Object and Space Perception Battery [33], Rey–
Osterrieth Complex Figure recall, to test visuospatial long-term memory, Rey–Osterrieth
Complex Figure, copy to test visuoconstructional abilities [34]. (5) Phonemic and semantic
fluency [35], language—Graded Naming Test [36], Word Comprehension—Synonyms Test
[37]. (6) Executive functions—phonemic word fluency [38]. (7) Frontal Assessment Battery—
FAB to assess frontal functionality [39].
For neuropsychological measures, age-, gender-, and education-corrected scores and equiva‐
lent scores should be calculated from the raw scores according to normative standards.
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3. Brain tumors and cognition
Cognitive impairment, a common finding with the brain tumors, may result from the tumor
itself or the treatment used surgery, chemotherapy, or RT.
3.1. Cognitive impairment due to tumor
More than 90% of patients with brain tumors showed impairments in the cognition at least in
one area. The reported impairments of executive function were observed in 78%, while
impairments of memory and attention were presented in more than 60% of patients [40].
Zucchella et al. [41] reported cognitive impairment in 54.4% of brain tumor patients, (53.75%)
presented with multidomain impairment, while (46.25%) of the patients revealed cognitive
deficits 16.25% of them limited to language, 13.75% to memory, 8.75% to attention, 6.25% to
logical-executive functions, and 1.25% to visuospatial abilities.
Talacchi et al. [5] reported cognitive impairment in glioma patients 79% of patients have
cognitive deficit in at least one test, (24, 3, 31, and 21% in one, two, three, four, or more tests,
respectively, and this was correlated with edema, tumor grade, and size. Verbal memory,
visuospatial memory, and word fluency were the most frequently affected functions.
3.2. Pathophysiology
Cognitive impairment associated with brain tumors can be induced by direct or indirect
compression of normal brain tissue by reactive edema [42].
Tumor tissue can also invade directly into functional brain regions or indirectly disconnect the
structures which can further contribute to cognitive deficits [43].
The mechanisms via which brain tumors affect brain function varied, highly malignant tumors
grow quickly so they tend to infiltrate and displace the normal brain tissue, while the lower
grade tumors tend to grow and infiltrate slowly disrupting brain function causing cognition
deficit.
Tumors of ventricular system causes increase in intracranial pressure and hence affect the
cognitive function; also large ventricular tumors affect the cognition directly through its
compression effect. Functioning brain tumors which secrete hormones may have role in
cognitive deficit through endocrine disturbance [44].
The main pathophysiology causes of cognitive dysfunction are not well known, different
hypotheses were placed; progression of brain tumors seems to be the predominant one [45],
also late treatment effects, for example, surgery, RT, chemotherapy, uses of antiepileptic drugs
or corticosteroids), the psychological distress also may contribute in cognitive dysfunction [46].
The cognitive function disturbance in brain tumors may be due to combination of these factors.
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4. Brain tumor surgery and cognition
In brain tumors, the first treatment modality is surgery. The aim was to balance the neurolog‐
ical outcomes (minimize the neurological deficits) and oncological outcome [2].
• Does brain surgery improve cognitive deficit?
Surgery for brain tumors improves the cognitive function due to the reduction of compres‐
sion as after removal of noninvasive tumors, such as meningiomas, improvement of atten‐
tional function occur [42]. Patients with high-grade glioma have worse cognitive dysfunction
than patients with low-grade glioma (LGG) [47]. The worse cognitive deficits in patients with
high-grade gliomas have been attributed to higher incidence of intracranial hypertension, the
rapid growth, and the infiltrative nature.
Sweet et al. [48] reported that the localization is associated with cognitive effects. Tumors of
the pineal region associated with memory impairment, visuospatial function, attention,
visuomotor function, problem-solving, and affective disorders.
Medial temporal lobe epilepsy caused by tumor is associated with cognitive deficit (long-term
memory dysfunction, difficulties in learning, attention, naming, visuospatial abilities,
executive functions, and intelligence) [49].
Less extensive surgery of the mesiotemporal structures correlates with better memory outcome
than in the extensive temporal lobe surgery [50].
Verbal memory decline was observed in dominant temporal lobe resection [51], while
visuospatial memory decline associated with nondominant temporal lobe resection [52].
Cognitive improvement has been observed after tumor resection, and improvement of verbal
memory has been observed after LGG resections in frontal premotor and anterior temporal
areas [4], usually after a transient postoperative worsening. This improvement was related to
tumor lateralization [53].
Some studies reported postoperative cognitive worsening in (38%) of patients versus 24% rate
of improved patients. Worsening associated with executive functions while improvement was
observed with memory function. This worsening may correlate to volume of the operated
area (tumor size) rather than the location. The postoperative improvement of memory
function, the most frequent preoperative cognitive deficit, occurs due to release of the mass
effect [54].
Teixidor et al. [4] reported immediate postoperative worsening for working memory in 96%
of cases, and Giovagnoli et al. [55] reported that postoperative scores for cognitive tests were
not significantly lower than the preoperative.
Talacchi et al. [5] found unexpected low incidence of additional deficits (38%) immediate
postoperative and a considerable rate of early improvement (24%), and this correlated with
tumor size and histology. This study reported also that postoperative worsening seems to be
due to a generic mechanical effect and to manipulation/removal of tumor periphery rather
than to discrete focal injury.
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Yoshii et al. [53] reported that the cognitive functions in patients with LGG and meningio‐
mas (MGs) in the right brain were normal preoperative and postoperative whereas it de‐
creased preoperative and did not return to the normal scores postoperative in left brain MGs.
Temporal and spatial orientation, similarities, first recall, writing, mental reversal decreased
after operation.
The explanation of mild cognitive effects in MGs preoperatively is the ability of normal brain
tissue to compensate as the slow growth of tumor provides enough time for this compensa‐
tion, but after surgical decompression decline in brain function occurs due to remodeling of
normal brain tissue [56]. Another explanation is that extracerebral tumor causes compres‐
sion on brain tissues but local anatomical and functional integrity maintained before surgery.
Stability of cognitive function also was observed after tumor resection, like tumors of third
ventricle; the preoperative cognitive impairment in executive function, memory, and fine
manual speed did not improve or worsen postoperatively [57].
Postoperative cognitive defects in specific domains were observed, for example, some patients
with frontal or precentral tumors showed postoperative minor deterioration in attention [58].
Right prefrontal cortex resection in one study [8] was associated with selective attention
impairment (Stroop test performance).
5. Effect of brain RT on cognition
Cognitive deficits following RT are irreversible and progressive complication that may follow
RT by several months to many years. These deficits may be due to vascular injury, local
radionecrosis, and cerebral atrophy, the severity ranges from mild or moderate to progres‐
sive mental slowing, occurring in at least 12% of patients who were treated with radiation
therapy [59].
5.1. Hypothesis of radiation-induced cognitive impairment
There are many hypotheses that explain how the cognitive deficits following radiation therapy
occur, direct damage and subsequent death of parenchymal cells (oligodendrocytes, neu‐
rons, astrocytes, and microglia) or indirect through reactive oxygen species (ROS) production.
Dynamic interactions between the multiple cell types (astrocytes, endothelial cells, microglia,
neurons, and oligodendrocytes) within the brain may be the cause of radiation-induced
cognitive impairment [60]. Another hypothesis is that the RT can inhibit hippocampal
neurogenesis causing the cognitive impairment.
Irradiation of the hippocampus results in loss of neuronal stem cells (NSCs) which are
responsible on self-renewal and generating neurons, astrocytes, and oligodendrocytes [61].
The radiation injury to NSCs is dose-dependent [62] and results in decrease in proliferation of
NSCs and decrease in its differentiation into neurons [63]. Radiation therapy for brain tumors
may lead to a significant reduction in the number of neurogenic cells [64].
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Direct damage of parenchymal brain cells due to RT and subsequent death of these leads to
cognitive impairment; damage to oligodendrocytes, responsible for myelination, has been
thought to play a role [65]. Neuronal irradiation of rodent causes altered expression of the gene
activity-regulated cytoskeleton-associated protein, N-methyl-D-aspartate (NMDA) receptors,
glutaminergic transmission, and also hippocampal long-term potentiation [66].
Disruption of the blood–brain barrier (BBB) as a result of brain RT has been associated with
impaired cognition. This disruption and alteration of the BBB is likely due to imbalance
between matrix metalloproteinase-2 and the metalloproteinase-2 tissue inhibitor levels [67],
activation of microglial cells plays an important role in phagocytosis of dead cells, sustained
activation is thought to contribute to a chronic inflammatory state in the brain [68]. Subse‐
quent inflammation following RT and cell death usually associated with up regulation of
cytokines, which are thought to be expressed by microglia, and pro-inflammatory transcrip‐
tion factors in the brain which contribute to endothelial cell dysfunction [69]. Glial and
endothelial cells appear to have independent and overlapping roles in the pathogenesis.
Ionizing radiation produces its effect by direct DNA damage or indirect through generating
ROS, leading to DNA damage to and activation of early response transcription factors and
signal transduction pathways [70]. Activation of these pathways leads to the following:
changes in cytokine milieu; the activation/influx of inflammatory cells, particularly micro‐
glia; marked increase in expression of the pro-inflammatory genes tumor necrosis factor (TNF)-
α, interleukin (IL)-1β, IL-6, and Cox-2, and the chemokines, Monocyte Chemoattractant
Protein-1 (MCP-1), intercellular adhesion molecule (ICAM)-1 and the development of post-
irradiation complications [71].
Radiation injury to astrocytes makes them to undergo proliferation, exhibit hypertrophic
nuclei/cell bodies, and show increased expression of glial fibrillary acidic protein .These
reactive astrocytes secrete a host of pro-inflammatory mediators such as cyclooxygenase
(Cox)-2 and the ICAM-1, which may lead to infiltration of leukocytes into the brain via BBB
breakdown [72].
RT affects large- and medium-sized blood vessels of the brain. Vascular hypothesis predicts
that blood-vessel dilatation, wall thickening with hyalinization, endothelial cell loss and a
decrease in vessel density, all these finally lead to white-matter necrosis [73].
The severity of cognitive deficit following radiation therapy appears to be proportional to the
dose of radiation therapy received by the hippocampus region [74].
5.2. Predisposing factors
Older ages more than 60 years and in some studies more than 40 years old have increased risk
to develop leukoencephalopathy specifically in patients with genetic predisposition to
leukoencephalopathy [75] with subsequent cognitive deficit. Also patient with white matter
disease such as multiple sclerosis have increased risk, also vascular diseases such as hyper‐
tention carry risk [76].
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Beside the previous patient-related factors, also there are factors related to treatment include
the dose of RT received, dose per fraction and volume of irradiated brain, 5% of patients treated
with more than 5000 cGy develop radiation necrosis [77], high radiation dose increases the risk
of leukoencephalopathy, daily doses >200 cGy have a significantly increased risk of cogni‐
tive damage [75]. The large irradiated volume of brain tissues carries increased risk of cognitive
impairment, and whole brain radiation has threefold to fourfold increased risk of encephal‐
opathy [76].
Additional treatments to RT such as chemotherapy have increased risk on cognition than RT
alone, systemic and intrathecal treatments have been implicated. Methotrexate chemothera‐
py when received intravenously or intrathecally after cranial irradiation has an effect on
cognition in children and also on adults [78].
5.3. Neuropsychological assessments
Folstein MMSE is brief test that assess delirium or significant dementia. It does not adequate‐
ly measure all the cognitive areas affected by radiation, and it is not a sensitive tool for detecting
cognitive impairment in patients receiving RT [79].
Among the patients who have impaired cognitive function by neuropsychological testing,
only 50% were considered abnormal on the MMSE [80].
The National Cancer Institute (NCI) Radiation Oncology Branch adapted the Meyers et al. [45]
test battery by adding few measures to assess processing speed, working memory, and
attention, which are functions that can be affected by RT [81].
Measurement of quality of life and daily activities of living is an important issue beside the
neuropsychological testes, such as the Barthel index to assess the daily living skills and the
Functional Assessment of Cancer Therapy-Brain (FACT-Br), to address the quality of life issues
concerning brain tumor patients undergoing treatment The Barthel Index assesses daily living
skills [82], and the FACT-Br was developed specifically to address the quality of life issues
concerning brain tumor patients undergoing treatment [83].
5.4. Cognitive impairment following RT
RT is the leading cause of cognitive deficits involving multiple domains, including memory,
attention, executive function, and intelligence.
Patients who received RT performed worse in measures of executive function and informa‐
tion processing speed. Worse cognitive functioning also observed with white-matter hyper‐
intensities and global cortical atrophy [84].
Several studies assed cognitive defects to specific tumor-type and tumor location. Aarsen et
al. [85] reported cognitive deficit, with sustained speech and speed of speech in children treated
with RT for pilocytic astrocytoma, 60% of patients had difficulty with academics 3 years after
treatment.
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Cognitive impairment observed in children with medulloblastoma who had treated with RT.
These deficits were prominent attention deficits correlated with impaired math and reading
performance [86].
Hoppe-Hirsch et al. [87] conducted a study comparing intellectual outcomes of children
diagnosed with ependymomas or medulloblastomas, treated with whole-brain radiotherapy
(WBRT), and found that only 10% of medulloblastoma patients had an IQ above 90 after 10
years compared to 60% of ependymoma patients, and this result attributed to cerebral
hemisphere radiation.
Posteroir fossa irradiation with 35 Gy was associated with lower cognitive scores than that
irradiated with a dose 25 Gy, and IQ and verbal comprehension seems to be dose-dependent
in posterior fossa tumors [88].
Large-sample controlled clinical trial conducted by Klein et al. [75] assed mid-term and long-
term neuropsychological function following the RT in LGG. In the study, 195 patients with
LGG compared with 195 healthy controls and 100 patients with hematological malignancies
with mean follow-up period of 6 years. The results revealed that patients with LGG had lower
scores in all cognitive domains than the controls and hematological patients, and the main
cause of cognitive deficits was the tumor, but cognitive deficits of memory domain was
observed only in patients who received RT with dose per fraction more than 2 Gy.
Another study was conducted on those patients after 12-year follow-up and found that the
attentional deficits deteriorated in patients who received RT. The progressive decline was
found even in patients received <2 Gy dose per fraction [89].
Decline in nonverbal memory was observed in patients with LGGs years post-RT, despite the
long-term improvements which observed in verbal memory, attention, and executive
function [84]. Postoperative RT in LGG was found to have a significant risk of long-term
leukoencephalopathy and cognitive impairment [90].
The irradiated volume of brain tissue has great impact on cognition. A study conducted by
Jalali et al. [91] reported that patients who treated with stereotactic conformal RT presented
with unchanged overall mean full-scale IQ, while one third of patients showed a >10% decline
in full-scale IQ as compared to baseline.
Chang et al. [92] found that cognitive deficits after the treatment with sterotactic radiosur‐
gery (SRS) had lower incidence than that in patients treated with whole-brain radiotherapy
(WBRT). The cognitive deficit in learning and memory function was (24%) in patients treated
with SRS and (52%) in patients treated with WBRT and SRS.
Intensity-modulated radiotherapy (IMRT) is a type RT technique in which more sparing of
normal brain tissue can be achieved and precise contouring to the tumor tissue.
Hippocampal sparing with IMRT reduced doses delivered to hippocampus by 87% (0.49 Gy)
and 81% (0.73 Gy) [93].
Proton beam therapy results in greater sparing of healthy brain tissue and allows for a more-
targeted delivery of radiation and smaller penetration of tissue beyond the tumor [94]. The
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mean dose of radiation to the hippocampus could be reduced much more, and it could be half
that of IMRT and consequently reduce the risk of cognitive deficit after RT [95].
6. Effect of chemotherapy on cognition
Chemotherapy treatment in brain tumor seems to have a role in cognitive deficits. There is
association between chemotherapy used in the treatment of brain tumor and an increased risk
for cognitive dysfunction especially, if it is administered with RT.
6.1. Pathogenesis of cognitive impairment
The mechanisms by which chemotherapy-induced cognitive impairment are unclear [96].
Chemotherapy may reduce the number of neural stem/progenitor cells, which have role in
memory and learning ability [97], and neural precursor cells are chemo-sensitivity, neural
stem, and line age-restricted progenitor cells that form, among other cell types, the myelinat‐
ing oligodendrocytes in the frontal white matter [98].
Primary pathological lesions including demyelination, inflammation, and microvascular
injury [99]. Also mature oligodendrocytes are chemo-sensitive at lower dosage than those
required to kill tumor cells [100].
Multiple chemotherapeutic agents affect hippocampal neurogenesis causing decrease in cell
proliferation within the germinal region of the hippocampus and development of cognitive
deficit [101].
Genetic role in chemotherapy-induced cognitive decline may be impilicated, and there is
increased risk of cognitive impairment after RT with the apolipoprotein E4 alleles [102].
6.2. Cognitive impairment of chemotherapeutic agents
Chemotherapy added to slow the tumor progression especially in children to postpone
radiation therapy or to reduce the dose of radiation therapy to decrease the neurocognitive
sequelae of increasing doses of RT. Neurotoxic side-effects of chemotherapy alone can be
difficult, because most patients of brain tumor have been treated with RT and chemotherapy
[103].
The evidence that chemotherapy alone causes neurocognitive effects is not consistent. Studies
have concluded that chemotherapy effects are negligible and not clinically significant
compared to craniospinal irradiation (CSI) [104].
Neurotoxicity of chemotherapy arises during, or shortly after, chemoterapy. RT causes
disturbance in BBB, so the toxicity of chemotherapy increased when was given during or after
RT. In these cases, the chemotherapeutic drugs reach higher concentrations in brain tissue
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because of leakage of the blood–brain barrier due to RT. Intrathecal chemotherapy has higher
CNS toxicity compared to systemic chemotherapy [105].
Chemotherapeutic agents, such as BCNU, CDDP, cytosine arabinoside, and intrathecal or
intravenous methotrexate, have toxic effect to the CNS. Chemotherapy-related cognitive
impairment in primary CNS lymphoma was observed in one or more domains: (attention,
executive function, memory, psychomotor speed, and language). Other studies have shown
that cognitive stability or cognitive improvement during chemotherapy provided that the
tumor was responsive to chemotherapy treatment [106, 107]. Uses of high-dose IV methotrex‐
ate or interathecal methotrexate with radiation therapy result in dementia particularly when
the radiation is given prior to the methotrexate. Leukoencephalopathy more commonly occurs.
MRI shows bilateral periventricular white matter changes. The radiation therapy disrupts the
BBB and results in increased permeability of the white matter to the methotrexate [108].
Copeland et al. [109] concluded that chemotherapy had only a slight effect on neurocogni‐
tive status and was confined to perceptual motor skills with observed age effect on perform‐
ance IQ.
Chemotherapeutic agents, such as BCNU, cisplatin, and cytarabine, have proved to be more
toxic to neural precursor cells than cancer cells [110]. Carmustine, methotrexate, and cytara‐
bine have been found to induce central neurotoxicity to neural stem cell populations located
in the subventricular zone and dentate gyrus [99].
Prabhu et al. [111] conducted a study on LGG patients and concluded that the addition of
chemotherapy procarbazine, lomustine, and vincristine (PCV) to RT for LGGs did not result
in significant MMSE score decline when compared to RT alone.
Regarding the HRQOL, there is a short-lasting negative impact of PCV chemotherapy on
HRQOL during and shortly after treatment, but no long-term effects on HRQOL have been
established [112].
Patients with previously untreated anaplastic astrocytoma, OA, or oligodendroglioma were
evaluated for the long-term efficacy and safety of accelerated fractionated RT combined with
intravenous carboplatin. In a phase II study conducted by Levin et al. [113], they found that
after RT, patients received procarbazine, lomustine (CCNU), and vincristine (PCV) for 1 year
or until tumor progression, 10% of those patients developed serious clinical neurologic
deterioration and/or dementia requiring full-time caregiver attention.
Hilverda et al. [114] reported that glioblastoma patients undergoing RT with concomitant and
adjuvant temozolomide treatment did not develop cognitive deterioration.
In LGG patients, temozolomide is not only successful in terms of extending the survival
duration but also has been proven to maintain or even improve HRQOL while patients are on
treatment [115].
Patients with recurrent high-grade glioma (HGG), successfully treated with temozolomide,
achieved significant improvement in the HRQOL domains, whereas patients with disease
progression had significant deterioration in most HRQOL domains [116].
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7. Prevention or reduction of cognitive deficits during treatment of brain
tumors
Reduction in treatment-related brain tissue toxicity has occurred with advances in neurosur‐
gical techniques, advances in radiation therapy techniques, and use of neuroprotective agents.
7.1. Pharmacological prevention of neurocognitive impairment
Neuroprotective agents may be used to protect healthy tissue against neuronal cell death or
degeneration caused by the treatment of brain tumor.
Lithium can be used to protect progenitor cells in the hippocampus through inhibition of
radiation-induced apoptosis and induction of the DNA repair, and the tumor cells not included
in this protection process. A study conducted by Yang et al. [117] found that neurocognitive
performance in mice was improved after receiving lithium concomitant with RT, anthor
neuroprotective drug; fenofibrate which prevents activation of microglia. Administration of
fenofibrate during whole-brain RT prevents effects on hippocampal neurogenesis in mice, as
it enhances survival of newborn neurons in the dentate gyrus [118].
7.2. New treatment techniques
The use of image-guided surgery such as the intraoperative magnetic resonance imaging
resulted in improvement in tumor resection and reduction of residual [119]. The use of
endoscopic biopsy is a minimally invasive method can be performed safely in conjunction with
diversion of cerebrospinal fluid in cases of obstructive hydrocephalus and decrease neuro‐
cognitive decline [120].
New radiation techniques such as IMRT are able to minimize the radiation to healthy brain
structures. With using IMRT, hippocampus can be localized and hence the dentate gyrus can
be spared, resulting in prevention or decrease neurocognitive decline to some extent [121]. Lin
et al. [122] reported significantly lower rates of memory loss posttreatment and with no
treatment-related decline in quality of life with IMRT RT.
Insignificant neurocognitive decline was found in a study conducted by Wahba et al. [123]
after use of reduced CSI followed by adjuvant chemotherapy in patients with average-risk
medulloblastoma.
With proton beam RT, there is less radiation to surrounding normal brain tissues and decrease
the area at risk for radiation injury, therefore, sparing of neurocognitive functioning [124].
7.3. Stem cell implantation
Mesenchymal stem cell implantation may reduce the cognitive impairment by two mecha‐
nisms: First, reversal of inflammatory process, as implanted mesenchymal stem cells can
migrate to the site of damaged brain tissue and then release growth factors, [125]. Second,
human mesenchymal stem cells can differentiate into neurons in the hippemocampal area and
prevent radiation-induced late cognitive impairment [126].
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8. Rehabilitation
Patients with brain tumors face the challenge of cognitive impairment due to the tumor itself
or treatments. Cognitive deficits in processing speed, memory, attention, and executive
functions interfere with patients’ relationships, occupational activities and daily life activities.
8.1. Pharmacologic treatment of neurocognitive impairment
Methylphenidate (MPH) is a CNS stimulant that increases synaptic concentration of dopa‐
mine and noradrenaline in the brain [127]. De-Long et al. [128] conducted a pilot study on
children with ALL or brain tumor, they found that approximately 75% of those patients had
response to treatment with MPH regarding neuropsychological dysfunction.
Meyers et al. [129] reported significant improvements in processing speed, memory, mental
flexibility, and even mood, in adult patients with brain tumors and receiving MPH. Conklin
et al. showed encouraging results in the use of psychostimulant medication. On 122 survi‐
vors of childhood brain tumors or ALL who were enrolled in a double-blinded, cross-over trial
comparing the acute efficacy and adverse effects of MPH and placebo.
Donepezil is acetylcholinesterase inhibitor and has efficacy in the treatment of cognitive
functions impairment; uses of donepezil in adult patients with brain tumors treated with RT
demonstrate improvements in cognition impairment such as attention, concentration, and
verbal memory [130].
However, stimulant medication is short-acting and is not expected to result in long-term
improvement in academic achievement and neurocognitive functioning once it is discontin‐
ued; on the other hand, newer pscyhostimulant medications have been widely used in children
with attention-deficit hyperactivity disorder (ADHD) and have proven to have fewer side
effects and a longer half-life than MPH, for these reasons further studies are needed [131].
8.2. Cognition rehabilitation program
Cognitive rehabilitation program has proven to be effective in in-patients with primary brain
tumors. The program consists of psychoeducation, teaching of strategies to compensate for
problems in attention, memory, and executive functioning in daily life.
Cognitive remediation program (CRP) highly structured and individualized regimen,
included traditional massed practice rehabilitation, instruction in metacognitive strategies,
and cognitive-behavioral psychotherapy focused primarily on improving resistance to
distraction. Butler and Copeland tested the effectiveness of CRP. Thirty-one subjects who had
been treated from CNS tumors included in the study, and they were suffering from cogni‐
tive impairment such as attention deficits documented by continuous performance test (CPT).
Cognitive behavioral psychotherapy was used. Significant improvement in focused atten‐
tion and attention/concentration was observed in those who underwent the CRP, but no
significant benefit was measured with regard to arithmetic computation. The authors
concluded that the intervention produced improved neurocognitive functioning on meas‐
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ures of attention, but that it was too early to expect a downstream effect on the desired end
result of improved academic achievement [132].
A study conducted by Butler et al. all patients was offered the CRP treatment, improvement
neurocognitive variables were observed but this was not statistically significant. The study
results demonstrated highly significant improvement in academic achievement for those who
completed the CRP, and significant gains in their child’s or adolescent’s attention/concentra‐
tion in activities of daily living [133].
The majority of the participants of cognitive rehabilitation program found the program to be
useful. However, older participants found the program more burdensome than younger
participants [134].
Richard et al. [135] conduct a study to compare two cognitive rehabilitation program, goal
management training (GMT) which is a neuroscience-based integration of mindfulness and
strategy training and the Brain Health Workshop (BHW) which offers supportive psychoedu‐
cation about living with a brain tumor. They found that significant improvement in execu‐
tive functions and greater attainment of pre-training functional goals in the GMT group while
The BHW group showed in significant improvement in mood and behavioral regulation.
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